论文部分内容阅读
目的分析新辅助化疗在腹腔镜手术治疗进展期胃癌中的临床疗效。方法从我科随机抽取50例进展期胃癌患者,在患者行腹腔手术前,采用FOLFOX4方案对50例患者进行术前新辅助化疗。结果通过新辅助化疗,50例患者的化疗毒副反应较低。其中26例(52%)肿瘤再分期降低,29例(58%)PR,7例(14%)CR,7例(14%)SD,5例(10%)PD,总有效率为72%(36 50)。在实施新辅助化疗7d~14d进行腹腔镜手术治疗,45例(90%)切除肿瘤,5例(10%)仅行腹腔镜探查未切除肿瘤,5例(10%)实施姑息性手术,9例(18%)相对根治切除,31例(62%)获根治性切除。结论在术前进行新辅助化疗对腹腔镜手术治疗进展期胃癌有明显疗效,可以有效提手术切除率,降低毒副反应,可充分发挥腹腔镜手术的微创优势。
Objective To analyze the clinical effect of neoadjuvant chemotherapy in the treatment of advanced gastric cancer by laparoscopy. Methods Fifty patients with advanced gastric cancer were randomly selected from our department. Before the patients underwent abdominal surgery, 50 patients were treated with neoadjuvant chemotherapy with FOLFOX4 regimen. Results of neoadjuvant chemotherapy, chemotherapy in 50 patients with low toxicity. Twenty-six patients (52%) had a lower total recurrence rate, 29 (58%) PR, 7 (14%) CR, 7 (14%) SD and 5 (10% (36 50). Laparoscopic surgery was performed 7 days to 14 days after neoadjuvant chemotherapy, 45 cases (90%) had tumor resection, 5 cases (10%) had laparoscopic resection without tumor, 5 cases (10%) performed palliative surgery and 9 Cases (18%) were relatively radical resection, 31 cases (62%) were radical resection. Conclusion Neoadjuvant chemotherapy before laparoscopic surgery for advanced gastric cancer has a significant effect, which can effectively improve the rate of resection, reduce side effects, which can give full play to the advantages of minimally invasive laparoscopic surgery.